Stanford Medicine researchers have started enrolling children younger than 12 in clinical trials to evaluate their response to the Pfizer-BioNTech COVID-19 vaccine. Stanford is serving as a site of the Phase 2-3 trial to determine whether the vaccine produces an immune response and prevents COVID-19 in children 5 through 11 years old. It is also a site of the Phase 1 trial to determine the appropriate dose of the vaccine for children 6 months to 5 years old.
